• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

    28.69 +0.26 (+0.91%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,829,042
    Open 28.08
    Bid (Size) 28.00 (100)
    Ask (Size) 29.29 (100)
    Prev. Close 28.43
    Today's Range 27.89 - 29.32
    52wk Range 16.24 - 45.30
    Shares Outstanding 308,456,852
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
    It has been a banner year for biotech buyouts, and these are two of the prime targets. 
    Via The Motley Fool
    News headline image
    Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
    Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement 
    From Calidi Biotherapeutics, Inc
    Via GlobeNewswire

    Performance

    YTD
    +33.4%
    +33.4%
    1 Month
    +0.7%
    +0.7%
    3 Month
    +70.8%
    +70.8%
    6 Month
    +27.3%
    +27.3%
    1 Year
    -14.3%
    -14.3%

    More News

    Read More
    News headline image
    Legend Biotech Corporation Announces Pricing of Public Offering
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short ↗
    Via Chartmill
    News headline image
    Legend Biotech Corporation Announces Proposed Public Offering
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Via Chartmill
    News headline image
    Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗
    Via MarketBeat
    News headline image
    Legend Biotech Announces Presentations at ASCO 2026
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    With YMM Down 29%, First Beijing Bought 13 Million More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Legend Biotech (LEGN) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Legend Biotech Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Matthews Just Slashed Its Futu Position -- Here’s Why That Matters ↗
    Via The Motley Fool
    News headline image
    Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    News headline image
    Why Legend Biotech Stock Crushed the Market on Monday ↗
    Via The Motley Fool
    News headline image
    Legend Biotech (LEGN) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Legend Biotech (LEGN) Q2 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗
    Via The Motley Fool
    Topics Earnings Economy World Trade

    Frequently Asked Questions

    Is Legend Biotech Corporation - American Depositary Shares publicly traded?
    Yes, Legend Biotech Corporation - American Depositary Shares is publicly traded.
    What exchange does Legend Biotech Corporation - American Depositary Shares trade on?
    Legend Biotech Corporation - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Legend Biotech Corporation - American Depositary Shares?
    The ticker symbol for Legend Biotech Corporation - American Depositary Shares is LEGN on the Nasdaq Stock Market
    What is the current price of Legend Biotech Corporation - American Depositary Shares?
    The current price of Legend Biotech Corporation - American Depositary Shares is 28.69
    When was Legend Biotech Corporation - American Depositary Shares last traded?
    The last trade of Legend Biotech Corporation - American Depositary Shares was at 06/26/26 04:00 PM ET
    What is the market capitalization of Legend Biotech Corporation - American Depositary Shares?
    The market capitalization of Legend Biotech Corporation - American Depositary Shares is 8.85B
    How many shares of Legend Biotech Corporation - American Depositary Shares are outstanding?
    Legend Biotech Corporation - American Depositary Shares has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.